Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

Approvals/CIMA-AEMPS/LENALIDOMIDA ACINO 25 MG CAPSULAS DURAS EFG

Approved

STANDARD

LENALIDOMIDA ACINO 25 MG CAPSULAS DURAS EFG

Acino Ag🇪🇸 Spanish Agency of Medicines and Medical Devices

Approval Date: Mar 28, 2022
Approval ID: d882cdb5f920819f
Company: Acino Ag
Type: Standard

Approval Details

Approval Id: d882cdb5f920819f
Drug Cima Aemps Name: LENALIDOMIDA ACINO 25 MG CAPSULAS DURAS EFG
Register Number: 86399
Holder Company Name: Acino Ag
Marketing Company Name: Acino Ag
Authorization Date: 2022-03-28
Dosage Form: CÁPSULA DURA
Dose: 25 mg
Route Of Administration: VÍA ORAL
Prescription Type: Uso Hospitalario
Commercialized: No
Company Name: Acino Ag

Active Ingredients

LENALIDOMIDA

25 mg

Approved

Quick Info

Agency

CIMA-AEMPS

Country

🇪🇸

Approval Date

Mar 28, 2022

Approval ID

d882cdb5f920819f

Type

Standard

Back to CIMA-AEMPS Approvals

LENALIDOMIDA ACINO 25 MG CAPSULAS DURAS EFG - CIMA-AEMPS Drug Approval Details